Although he’s educated as a gastroenterologist and scientist, Frédéric Marrache, MD, PhD, has all the time had one thing of an entrepreneurial itch. Following his post-doctoral program and a stint in administration consulting, he made his technique to Sanofi the place he would work on early- to mid-stage drug improvement applications targeted on immune-mediated illnesses.
“This was proper across the time when Sanofi, along with Regeneron, was finalizing the event of Dupixent,” a prescription biologic injection used to deal with a number of inflammatory circumstances, he informed GEN. These experiences gave him “significant insights” into affected person care in addition to about “how one can develop therapies on this house.”
A kind of insights was the size of the unmet medical want within the immune-driven inflammatory illness house. Although some massive pharma corporations have developed merchandise for the house already, “I had a couple of insights about what could possibly be differentiated,” he mentioned. That led him to interact with a group at Sofinnova Companions in early 2025. “I got here in with my insights about affected person wants, immunology, and goal choice, and [my] view on proper and fallacious property,” he mentioned. “They got here with expertise in constructing corporations” and “we mapped out your entire asset house particularly on the goal and pathway of curiosity.”
These discussions led to the launch of Bionyra Pharma, a clinical-stage biopharmaceutical firm that’s growing next-generation biologics for extreme immunological and inflammatory illnesses. The corporate emerged from stealth this week after elevating $165 million in an oversubscribed Collection A. The spherical was co-led by Jeito Capital and Sofinnova Companions with participation from Arkin Bio, Sanofi Ventures, Sixty Diploma Capital, Vives Companions and Apollo Well being Ventures.
Marrache serves because the co-founder and CEO of the corporate. Along with the financing, Mehdi Ainouche, companion at Jeito Capital; Anta Gkelou, companion at Sofinnova Companions; Avital Adler, principal at Arkin Bio; and Laia Crespo, companion at Sanofi Ventures, will be part of Bionyra’s board of administrators.
“After we co-founded Bionyra with Frédéric, our conviction in each the corporate and his management was grounded in his deep experience in immune and inflammatory illnesses,” mentioned Sofinnova’s Gkelou. “Trying forward, we’re targeted on advancing these applications with the intention of bringing significant new remedy choices to sufferers.”
Particularly, the funds will assist Bionyra’s efforts to advance mono and multispecific antibodies for numerous inflammatory circumstances together with atopic dermatitis and inflammatory bowel illness (IBD).
Proper out of the gate, Bionyra is launching a pipeline of three scientific and near-clinical anti-inflammatory therapies, a few of that are already in scientific trials. The corporate’s first asset, BYN-002 is a TL1A monoclonal antibody with the potential to deal with IBD and different TL1A-relevant indications. This remedy is at the moment in a fully-enrolled Part I research in wholesome folks. Its subsequent candidate, BYN-003, is a TL1A*IL-23p19 bispecific antibody that can be in Part I testing. Each property have been improved with half-life extension (HLE) engineering to maximise efficacy and affected person profit.
Typically talking, “TL1A is a sport changer goal proper now in [immunology and inflammation] with nice ends in inflammatory illness,” he mentioned. Nonetheless, it’s seemingly that this goal will likely be related throughout a number of indications. To that finish, Bionyra is protecting its choices open when it comes to what it would goal with its TL1A property. “Whether or not it’s going to be within the inflammatory bowel illness house, whether or not we go for one more indication house or whether or not we determine to develop it together in any of those indications, that’s an possibility,” he mentioned.
For now, the main target is on validating the protection and efficacy of each therapies in wholesome volunteers. “That’s particularly a query across the bispecific antibody” as a result of there’ll seemingly be questions across the immunogenicity, he famous. “Our benefit right here is that our bispecific is constructed on the spine of our monospecific, so no less than now we have some degree of early validation right here, and we hope to current some outcomes quickly.”
A 3rd candidate, BYN-001, is an IL-25 monoclonal antibody that has additionally benefited from HLE know-how. It’s at the moment within the IND-stage for atopic dermatitis and kind 2 irritation. Whereas there are a number of property in improvement that intention to focus on sort 2 irritation, as soon as the entire me-too medication are excluded, the sector turns into narrower, Marrache mentioned whereas explaining the rationale for selecting this specific drug candidate for Bionyra’s portfolio. “IL-25 has been identified to be a robust driver of sort 2 irritation for a while,” he mentioned.
Moreover, some just lately printed early scientific knowledge from a competitor, who’re growing their very own asset for IL-25, “clearly validated the pathway and prompt potential for differentiation.” On the time, Bionyra was already exploring the identical goal house so “we had been in a position to transfer in a short time” and discover what, Marrache believes, is the “most potent IL-25 antibody on the market” with the “longest half life.”
Two of the property BYN-002 and BYN-003 had been licensed from TrueLab Biopharmaceutical. Below the phrases of the settlement Bionyra was granted unique worldwide rights, excluding Better China, to analysis, develop, manufacture and commercialize each therapies. TrueLab is eligible to obtain as much as $985 million in complete consideration associated to each property, together with the upfront cost in addition to improvement, regulatory, and industrial milestone funds. The settlement additionally contains tiered royalties on future internet gross sales. As well as, TrueLab has a single-digit fairness stake in Bionyra Pharma following completion of its Collection A financing.
For its half, BYN-001 was licensed from NovaRock Biotherapeutics. Bionyra can be progressing further preclinical property together with some from TrueLab. It’ll assist these efforts with among the funds from the Collection A.
